P-labeled mouse PPAR-72 cDNA as a probe, we screened ~1 X 10 6 clones of a human genomic DNA library. Genomic DNA from the 23 positive clones was isolated and subjected to Southern blot analysis with the same mouse probe. The resulting six positive fragments were subcloned, subjected to DNA sequencing, and found to encompass the entire coding regions of both the human PPAR-71 and PPAR-72 genes and a part of 5 The open reading frames of the human PPAR-71 and PPAR-72 genes are contained in six and seven exons, respectively. The predicted human PPAR-72 protein contains an additional 28 amino acids at the amino terminus compared with human PPAR-71 (10). These additional amino acids are encoded by a single exon, designated exon 72. The six downstream exons, shared with the PPAR-71 and PPAR-72 genes, are designated exons 1 to 6. The exon-intron boundaries were identified with the use of the human PPAR-7I and PPAR-72 cDNA sequences (10). The sequence of the protein-coding region of the PPAR-7 gene was identical to that of the corresponding human cDNA (10). As in the mouse PPAR-7 gene (9), the DNA-binding domain of human PPAR-7 is encoded by exons 2 and 3, and the ligand- Twelve Japanese individuals with lipoatrophic diabetes were studied (Table 1) . Subjects LD2 and LD3 were first cousins, and LD10 and LD11 were siblings from the same kinship; the other eight subjects were unrelated. All subjects except LD5, LD6, LD7, and LD12 were the offspring of consanguineous parents or had family antecedents with diabetes or lipoatrophy. All subjects except LD5 and LD12 also exhibited acanthosis nigricans. Hepatomegaly was present in all subjects except LD9. All 12 subjects showed hyperinsulinemia and abnormalities in lipid metabolism.
Genomic DNA was extracted from peripheral blood leukocytes of each subject. All participating individuals were informed of the aim of the study and gave their informed consent. The investigation was conducted according to the guidelines expressed in the Declaration of Helsinki. A total of 15 specific oligonucleotide primer sets were used for PCR-SSCP analysis (Table Al; shown on Diabetes website). The entire protein-coding regions of both the PPAR-71 and PPAR-72 genes including exon-intron boundaries and the partial 5' upstream region of PPAR-72 gene were amplified successfully with these primer sets. We divided each of exons 1 to 6 and exon 72 with the partial 5' upstream region into two and three partially overlapping sequences, respectively, for PCR amplification in an attempt to increase the sensitivity of SSCP analysis. PCR products that showed abnormal migration on SSCP analysis were subjected to direct sequencing.
We detected a silent CAC (His) -> CAT (His) mutation at codon 447 in exon 6 of subject LD12, and an intronic T -> C transition 22 bp upstream of exon 2 in subject LD7 and LD10. However, neither significant mutations in the protein-coding region of the PPAR-7 gene nor polymorphisms in the partial 5' upstream region of PPAR-72 gene were detected. The exonic silent mutation was also detected in 9 of 27 normal control subjects, indicating that it is not relevant to the pathogenesis of lipoatrophic diabetes. The intronic T -> C transition did not affect a splicing site.
In the result, no mutations that affect the amino acid sequence of PPAR-7 were detected in any of the 12 subjects, indicating that such mutations do not appear to be a major cause of lipoatrophic diabetes. Although it was shown that C/EBPp is induced early phase in adipogenesis and increases the expression of PPAR-7 (11), there were no polymorphisms in the partial 5' upstream region of PPAR-72 gene that contains the consensus binding sequence of C/EBP. However, we did not analyze the entire PPAR-7 gene; it is thus possible that mutations in the farther 5' upstream region or in intronexon-bordering regions of introns impair gene transcription or result in abnormal RNA splicing and that such mutations might be the pathogenesis of lipoatrophic diabetes. At present, the targeted disruption of the PPAR-7 gene has not been reported, so the pathological conditions caused by gene deletion are not known. However, our results indicate that at least the coding sequences of the PPAR-7 gene are normal in individuals with lipoatrophic diabetes. It is therefore possible that abnormalities in the endogenous ligand for PPAR-7 are responsible for this disease.
Finally, our results suggest that thiazolidinedione drugs might be effective for the treatment of insulin resistance and lipodystrophy in patients with lipoatrophic diabetes, given that PPAR-7, the receptor for these agents, appears to be intact in such individuals.
